CN111712226A - 用于护理因微尘所造成的皮肤细胞损伤的含有梅花提取物的组合物 - Google Patents
用于护理因微尘所造成的皮肤细胞损伤的含有梅花提取物的组合物 Download PDFInfo
- Publication number
- CN111712226A CN111712226A CN201880075567.1A CN201880075567A CN111712226A CN 111712226 A CN111712226 A CN 111712226A CN 201880075567 A CN201880075567 A CN 201880075567A CN 111712226 A CN111712226 A CN 111712226A
- Authority
- CN
- China
- Prior art keywords
- composition
- plum blossom
- blossom extract
- less
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 239000000284 extract Substances 0.000 title claims abstract description 56
- 210000004927 skin cell Anatomy 0.000 title claims abstract description 29
- 230000005779 cell damage Effects 0.000 title claims abstract description 16
- 208000037887 cell injury Diseases 0.000 title claims abstract description 16
- 230000014509 gene expression Effects 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000000428 dust Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000002537 cosmetic Substances 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 210000002510 keratinocyte Anatomy 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 229940083365 prunus mume flower extract Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 238000009472 formulation Methods 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 230000036541 health Effects 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000006210 lotion Substances 0.000 description 9
- 239000004576 sand Substances 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 230000037380 skin damage Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000004809 Teflon Substances 0.000 description 5
- 229920006362 Teflon® Polymers 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- -1 foundation Substances 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000021018 plums Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241001164374 Calyx Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 229940060184 oil ingredients Drugs 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 235000004789 Rosa xanthina Nutrition 0.000 description 2
- 241000220222 Rosaceae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940116978 human epidermal growth factor Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000011882 ultra-fine particle Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 230000010558 Gene Alterations Effects 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100036679 Interleukin-26 Human genes 0.000 description 1
- 101710181612 Interleukin-26 Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical class CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
Abstract
本说明书公开了用于护理因微尘所造成的皮肤细胞损伤的组合物,该组合物包括梅花提取物以作为活性成分,且该组合物将IL‑36G(NM_019618)的表达水平调控至正常水平,IL‑36G是在皮肤细胞中的基因,其表达水平受到微尘所影响。通过使用用于护理因微尘所造成的皮肤细胞损伤的组合物,能够使微尘所改变的基因表达水平回到正常水平,且藉此护理皮肤细胞损伤。
Description
技术领域
本公开公开了一种用于护理因微尘所造成皮肤细胞损伤的组合物,特别是包含梅花提取物(Prunus mume flower extract)的组合物,该组合物通过显著地改变生物标志物等而护理皮肤细胞的损伤,该生物标志物是皮肤细胞基因,其表达水平相较于正常状态而言受到微尘所改变。
背景技术
皮肤是身体的一部分,直接暴露在外部环境中。皮肤不仅作为保护我们身体重要器官的保护层,也调节水分的蒸发,且保护身体免受外部感染。然而,即使皮肤是为了防止病毒从外部侵入,皮肤过度暴露于紫外线或污染物会引发皮肤发炎。尤其,与强风及脏污伴随而来的黄沙(Asian dust)使皮肤损伤。
黄沙是这样的现象:小沙子或红色黏土从中国、蒙古等内陆沙漠飘浮,因上风而远扬,然后落在地面附近。在韩国,每年春天都会定期发生黄沙。黄沙是有机和无机物质的组合,其物理特性和成分依照发生的时间和地点而定,存在相当的歧异。黄沙也包括能够产生生物效应的金属。大颗粒的黄沙通常留在它们的源头或周围,而其小型颗粒甚至进入韩国。根据报导,当吸入灰尘时,这些灰尘会沉积在下支气管中,甚至在肺的气体交换部分中,这可能对呼吸系统造成损害。此外,发现生活在尘土飞扬地区或有大量黄沙的地区的人们的皮肤中皮肤细胞的损伤增加。
IL-36G已知是由微尘造成的皮肤细胞损伤引起的干癣中的有用生物标志物。IL-36G对干癣发炎而言是具有特异性的,有别于如S100蛋白A7、A8和A9的类的生物标志物,且已知IL-36G在其他发炎皮肤病(如AD、CE和LP)中表达弱(参见非专利文献2)。
引用文献表
非专利文献
非专利文献1:Kim,H.J.等人,“空气中PM2.5诱导的对人类角质形成细胞的不利影响的转录体分析”(“Transcriptome analysis of airborne PM2.5-induced detrimentaleffects on human keratinocytes”),Toxicology Letters 273,26-35,2017年。
非专利文献2:AM D’Erme等人,“IL-36c(IL-1F9)是干癣皮肤病变的生物标志物”(IL-36c(IL-1F9)is a Biomarker for Psoriasis Skin Lesions),Journal ofInvestigative Dermatology,第135卷,2015年。
发明内容
本案的发明人已发现,微尘对皮肤有害,进而影响皮肤细胞基因的表达,引发诸如皮肤细胞损伤等症状。
因此,本发明的一个方面是,提供一种用于护理因微尘所造成的皮肤细胞损伤的组合物。
为了实现上述目的,本发明的一个方面提供了一种用于护理因微尘所造成的皮肤损伤的组合物,该组合物包含作为活性成分的梅花提取物,并且该组合物将IL-36G(NM_019618)的表达水平调控至正常水平,该IL-36G是皮肤细胞中的基因,其表达水平受微尘影响。
在一个方面中,通过使用本发明的用于护理因微尘而造成的皮肤细胞损伤的组合物,能够使因微尘而改变的基因表达水平回到正常水平,从而护理皮肤细胞的损伤。
附图说明
图1展示了当用微尘提取物处理时的细胞存活率。在此,ASDP(代表黄沙尘暴的颗粒)指的是黄沙,PM10(颗粒物10)是指粒径为10μm的微尘,而PM2.5(颗粒物2.5)是指粒径为2.5μm的微尘,图表中x轴上的值分别代表0μg/ml、6.3μg/ml、12.5μg/ml、25μg/ml、50μg/ml、100μg/ml、和200μg/ml的微尘水溶性提取物的浓度(μg/ml);
图2展示了IL-36G基因的mRNA表达水平在PM2.5微尘所刺激的皮肤细胞中增加,并通过以梅花提取物的处理恢复到正常水平。
具体实施方式
在下文中,将详细描述本发明。
梅(Prunus mume)是一种分类于蔷薇科(rosaceae rosales)的落叶树,源自中国,分布于日本、中国和韩国。这种花在韩文中称作maewha,翻译为梅花,果实在韩文中称为maesil,翻译为梅实。它高5到10米,树皮呈现各种颜色,如黄白色,绿白色及红色,而小枝条可(或可无)细毛。在韩国中部,于四月,梅花比叶子早一步绽放,颜色为不同深浅的白色和红色,并且有芬芳香气。花有5个圆形的花萼和几片花瓣,具有上下颠倒的宽广卵形。叶子是交替的叶序,卵形或宽卵形,长4至10公分。叶子的边缘有锋利的锯齿,两边都有毛,且叶柄上有线条。果实梅子是球状的核果,呈绿色,在七月成熟而转为黄色,直径为2至3公分,有致密的毛,味道酸,且果肉几乎不与果核分开。
取决于所要的用途、花色、和花瓣形状,有许多栽培品种。根据所要用途将其分为花梅和果实梅,花梅再分为接近野生植物的野生(yabai)型、源自野生栽培品种且有红色花朵的红色(hibai)型、及与杏子杂交的bungo型。根据花瓣的颜色,分为白色的梅(具有白色花朵)和红色的梅(具有红色花朵),且在白色的梅中,有白色花瓣但具绿色花萼的白色的梅被分类为绿色花萼形式。根据花瓣的形状,仅具有五片花瓣的花被分类为单花花形,而五片花瓣内有花瓣的花被分类为双花花形。
在本发明的一个方面中,用于护理因微尘所造成的皮肤损伤的组合物可包括梅花提取物作为活性成分。
在一个方面中,可将梅花干燥并粉碎。
在本发明的一个方面中,可以用特定的提取溶剂对梅花进行提取,而形成梅花提取物。
在本发明的一个方面中,可通过以水或有机溶剂提取梅花,而制备梅花提取物。
具体的,可以下述方式制备:以选自水、C1-C6的无水或水合低级醇、丙酮、丁二醇、乙酸乙酯、乙酸二乙酯、二乙醚、苯、氯仿、及己烷组成的群组的至少一种提取溶剂提取梅花。
在一个方面中,可在室温提取梅花提取物。
在一个方面中,梅花提取物可以通过下述方式获得:以提取溶剂提取,然后进一步执行以下步骤中的至少一步骤:过滤、浓缩、分离、或干燥。尤其,梅花提取物可进行至少一个过滤步骤。
在一个实施例中,该梅花提取物进行两个过滤步骤。
在一个实施例中,该分离步骤可包括离心步骤。
具体的,该提取可使用下述的至少一者:极性溶剂,包括水、C1-C6无水或水合低级醇、丙酮、及丁二醇;以及低极性溶剂,包括乙酸乙酯、乙酸二乙酯、二乙醚、苯、氯仿、及己烷。
更具体的,该溶剂可为50-90%的乙醇水溶液,且可为60-80%或65-75%的乙醇水溶液。当溶剂是50-90%的乙醇水溶液时,能够从梅花中有效地提取活性成分。在一个实施例中,该溶剂可为约70%的乙醇水溶液。
在一个方面中,提取后,可在蒸馏设备中在适当温度于减压浓缩该提取物,该蒸馏设备配备有冷凝器。
然而,根据本发明的梅花提取物可通过本领域中的已知方法提取而得,且该提取方法并不限于上述方法。
在本发明的一个方面中,基于组合物的总重量,该组合物可包含0.000001至30重量%的梅花提取物。当该梅花提取物的含量为0.000001至30重量%时,该梅花提取物获得了护理因微尘所造成的皮肤损伤的绝佳效果。
具体的,该含量可为0.0000001重量%或更多、0.0000005重量%或更多、0.0000007重量%或更多、0.0000009重量%或更多、0.000001重量%或更多、0.000002重量%或更多、0.000004重量%或更多、0.000006重量%或更多、0.000008重量%或更多、0.00001重量%或更多、0.00003重量%或更多、0.00005重量%或更多、0.00007重量%或更多、0.00009重量%或更多、0.0001重量%或更多、0.0003重量%或更多、0.0005重量%或更多、0.0007重量%或更多、0.0009重量%或更多、0.001重量%或更多、0.01重量%或更多、0.1重量%或更多、1重量%或更多、3重量%或更多、5重量%或更多、7重量%或更多、9重量%或更多、10重量%或更多、13重量%或更多、15重量%或更多、17重量%或更多、19重量%或更多、21重量%或更多、23重量%或更多、25重量%或更多、27重量%或更多、29重量%或更多、30重量%或更多、或31重量%或更多,且32重量%或更少、31重量%或更少、30重量%或更少、29重量%或更少、28重量%或更少、26重量%或更少、24重量%或更少、22重量%或更少、20重量%或更少、18重量%或更少、16重量%或更少、14重量%或更少、12重量%或更少、10重量%或更少、9重量%或更少、8重量%或更少、6重量%或更少、4重量%或更少、2重量%或更少、1重量%或更少、0.1重量%或更少、0.09重量%或更少、0.04重量%或更少、0.01重量%或更少、0.006重量%或更少、0.001重量%或更少、0.0009重量%或更少、0.0007重量%或更少、0.00005重量%或更少、0.00003重量%或更少、0.00001重量%或更少、0.000009重量%或更少、0.000007重量%或更少、0.000005%重量或更少、0.000003重量%或更少、0.000001重量%或更少、0.0000009重量%或更少、0.0000007重量%或更少、0.0000005重量%或更小、或0.0000003重量%或更少、0.0000002重量%或更少、0.0000001重量%或更少、0.00000009重量%或更少,但不限于此。
本发明的另一方面包括,该组合物用于护理因微尘造成的皮肤损伤的用途。
本发明的另一方面提供一种用于在受试者中护理因微尘造成的皮肤损伤的方法,该方法包括将有效量的梅花提取物给药至有需要的受试者。
本发明的另一方面提供了梅花提取物的用途,其用于制备用于护理因微尘所造成的皮肤损伤的组合物。
本发明的另一方面提供用于护理因微尘所造成的皮肤损伤的梅花提取物。
如本文所用,术语“微尘”是指肉眼不可见的非常小的物质。它是在空气中飘浮或飘动达长时间并且直径为10μm或更小的颗粒物。尤其,直径为2.5μm或更小的颗粒物被称为“超细颗粒”。在本发明中,“微尘”旨在包括“超细颗粒”。
如本文所用,术语“护理”是指有效保护皮肤细胞免受刺激和抑制,预防或恢复(回复)刺激所引起的特定基因表达水平的改变。
一个方面中,本发明提供了一种组合物,该组合物用于通过将微尘所损伤的皮肤细胞中的特定基因的表达水平调控至正常水平,而抑制微尘所造成的皮肤细胞的损伤。
具体的,在本发明的一个方面中,其表达水平受到微尘影响的皮肤细胞中的基因包括IL-36G(NM_019618)。IL-36G(NM_019618)是其表达水平因微尘而增加的基因。因此,能够通过将此基因的表达水平抑制到正常水平,而抑制皮肤细胞的损伤(参见非专利文献1)。
表1中显示了本发明中所用的基因,其表达水平因微尘而增加。在表中,术语“名称”表示NCBI的基因库登录ID,术语“基因符号”表示官方基因符号,并且术语“基因全称(gene title)”表示每个基因的名称。这些在非专利文献1中皆有描述。
[表1]
可以使用本领域已知的各种分析方法分析基因或蛋白质的表达水平,例如微数组、PCR、NGS(下一代定序)、西方墨点法(western blot)、北方墨点法(northern blot)、ELISA、放射免疫测定、放射免疫扩散法、免疫组织化学染色、及免疫沉淀测定。
微尘会对皮肤细胞造成损伤,而导致发炎,从而进一步损伤皮肤细胞。通过利用梅花提取物护理皮肤细胞损伤的恶性循环,能够改善皮肤状况。
在本发明的一个方面中,该组合物可以是化妆品组合物、药物组合物、或保健功能食品组合物。
化妆品组合物的示例包括化妆品,例如各种乳霜(cream)、润肤露(lotion)、和调理水(toner),和卸妆(cleansing)产品、卸妆水、肥皂、及化妆液。
在一个方面中,包含含有本发明的梅花提取物的组合物的化妆品可以是溶液、乳液、黏稠混合物等形式。
即,在一个方面中,本发明的化妆品的制剂并无特别限制,可以是例如乳液(emulsion)、乳霜、调理水、精华液(essence)、面膜(pack)、凝胶、粉末、化妆基底、粉底、润肤露、软膏、贴片、化妆液、卸妆泡沫、卸妆乳霜、卸妆水、身体润肤露、身体乳霜、身体保养油(body oil)、身体精华液、洗发精、洗剂(rinse)、洁肤露、肥皂、染发剂、或喷雾剂。
根据期望制剂或目的,本领域技术人员可毫无困难地选择除梅花提取物的外的成分并将其添加到每种制剂的化妆品组合物中。
此外,一个方面中,本发明的化妆品可包含选自水溶性维生素、脂溶性维生素、多胜肽、多醣、鞘脂质和海藻提取物的组合物。
在一个方面中,若需要,本发明的化妆品可含有除必需成分的外的一般用于化妆品中的成分。
额外成分的示例包括油脂成分、保湿剂、润肤剂、界面活性剂、有机和无机色素、有机粉末、紫外线吸收剂、防腐剂、消毒剂、抗氧化剂、植物提取物、pH调节剂、醇类、着色剂、香料、血液循环刺激剂、皮肤冷却剂、止汗剂、及纯水。
然而,化妆品中可含的成分不限于此。而且,可在不对本发明的目的和效果产生负面影响的范围内确定任何成分的量。
在一个方面中,包含本发明的梅花提取物的药物组合物可进一步包含已知上用于制备药物组合物的合适的载体、赋形剂、和稀释剂。
包含梅花提取物的药物组合物可以调配成适合药物制备的任何形式,根据已知方法,包括口服制剂,诸如片剂、胶囊、药粉、或糖浆,和用于皮肤外用的药剂,诸如软膏、凝胶、乳膏、贴片和喷雾。
一般而言,应理解由药物组合物所施用的活性成分的实际剂量应当按照各种相关因素决定,该因素诸如为受试者的症状的严重程度、给药途径、年龄、性别、体重、和健康状况。大致上,活性成分的剂量可以是0.0001mg/kg/天至3000mg/kg/天,例如10mg/kg天至500mg/kg/天。
在根据本发明的一个方面的保健功能食品组合物中,该保健食品可指由日常饮食中可能缺乏的营养素或者是对人体有用的功能的原料或成分(功能性原料)制成的食品,该食品通过维持人体的正常机能或活化生理机能来维持和改善健康,但不限于此。可将保健食品制造且加工成片剂、胶囊、粉末、颗粒、液体、药丸等形式。然而,该制剂不限于此,可将其制造和加工成任何符合法律的形式。
具体的,保健饮料组合物在作为必需成分而以预定比例包含的上述化合物的外的成分方面并无特别的限制。该组合物可含有各种调味剂或天然的碳水化合物以作为已知饮料中的额外成分。天然碳水化合物的示例是已知的糖,诸如单醣、多醣、和环糊精,以及糖醇,诸如木糖醇、山梨糖醇、和赤藓糖醇。而且,天然调味剂(索马甜(thaumatin)、甜叶菊提取物(例如甜叶菊苷A(rebaudioside A))、甘草素等)和合成调味剂(例如糖精、阿斯巴甜等)可用作调味剂。
一般而言,应理解由保健功能食品组合物所施用的活性成分的实际剂量应按照各种相关因素决定,该因素诸如为受试者的症状的严重程度、给药途径、年龄、性别、体重、和健康状况。通常,活性成分的剂量可以是0.0001mg/kg/天至1000mg/kg/天,例如0.02mg/kg/天至6mg/kg/天。
在下文中,将参考实施例更详细地描述本发明的构造和效果。然而,提供以下实施例仅为了说明,以助理解本发明,本发明的范畴并不限于这些实施例。
实施例1:梅花提取物的制备
使用提取溶剂,在室温下提取梅花,该提取溶剂是通过以3:7的比例混合纯水和乙醇而获得,即,以70%乙醇作为提取溶剂。在室温下提取后,执行初次过滤以除去提取物中所含的固体物质。接着,浓缩提取物以移除乙醇,然后分离和纯化。然后,将所得物进行离心和二次过滤,然后干燥以获得梅花提取物。
实施例2:微尘收集和提取
使用低容量空气取样器(美国佛州Gillian的Sensidyne公司)收集微尘。过滤组件的过滤器和固气分离器(denuder)在每个测量日的上午10:00左右更换,以收集样品约24小时。在首尔的顺风区域(京畿道龙仁市前宁区的韩国外国语大学外国语学院国际研究中心的住宅大厅的6楼屋顶)每天收集微尘达28天。测量时间是通过当打开真空泵时启动定时器并在关闭真空泵时记录定时器的时间而测量。收集流速设定为16.7升/分。在测量开始时用流量计(型号4143,TSI公司)测量流速,并在测量结束时再次测量。在收集的前和之后对过滤组件中的铁氟龙过滤器进行称重。在干燥器(日本NIKKO公司)中在相对湿度40%下将铁氟龙过滤器干燥至恒重达24小时,然后测量铁氟龙过滤器的重量,之后在小数五位的电子天平(DVG215CD,Ohaus公司)上称重两次。记录平均值。收集样品后,在测量重量的前,将铁氟龙过滤器再次在干燥器中干燥至恒重达24小时,然后称重两次。之后,通过将测量的重量与收集前所测量的重量进行比较,而计算质量浓度。通过以1mL的乙醇润湿铁氟龙过滤器,及加入14mL的DW来提取微尘,使得过滤器的气溶胶收集器表面到达水面,关闭盖,然后用超音波清洗器对过滤器施加超音波达30分钟。为了使过滤步骤中由水分引起的误差最小化,在干燥器中将水分完全地从过滤器中移除达48小时。然后,使用能够测量低至0.1mg的超精密测量仪器(Mettler Toledo公司)测量过滤器的重量,以测量提取前后的过滤器重量。
实施例3:角质形成细胞系的培养(正常人)
角质形成细胞系(正常人)购自Lonza公司(美国马里兰州Walkersville),传代培养,然后在CO2培养箱中在37℃和5%CO2的条件下培养。细胞培养是按照Lonza的指导方针执行。将KGM-2子弹套组(bullet kit)CC-4152(成分:BPE(牛脑下垂体提取物))、人表皮生长因子(hEGF)、胰岛素、氢羟肾上腺皮质素、转铁蛋白、肾上腺素、和KGM-2子弹套组CC-3107(添加有GA-1000(庆大霉素硫酸盐+两性霉素-B))加入到500ml的KBM-2CC-3103培养基中,以制备用于细胞培养的培养基。
实施例4:用微尘处理角质形成细胞系(正常人)并测量细胞毒性
为了调查以微尘处理的细胞毒性,根据Mossman等人的方法(J.Immunol.Methods,65,55-63,1983),用角质形成细胞系(正常人)执行MTT测定。
详细而言,使用24格板。将实施例3中获得的直径为2.5μm的微尘分散在纯水中,以制备微尘分散液。然后,将微尘分散液施加至在实施例4的条件下培养的细胞,且每格2.5×105个细胞,之后培养24小时。然后,将细胞与5mg/ml的MTT(溴化3-4,5-二甲基噻唑-2,5-二苯基四唑)混合,并在37℃下进一步培养3小时。然后除去培养基,将形成的甲(formazan)晶体溶解在500μl的DMSO中。将裂解物等份分配(aliquot)至96格板中,并在540nm处测量OD值。测量结果显示在图1中。
如图1所示,在细胞系中达到细胞毒性的80%存活率的浓度(IC20)是12.5μg/ml,该细胞毒性是由通过分散2.5微米或更小的微尘获得的分散体所造成。
实施例5:通过下一代定序调查因微尘所造成的细胞基因改变
为了进行RNA碱基序列数据处理和分析,参考Trapnell等人(2012年)所开发的一般分析步骤。使用FastQC(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/)确定RNA序列数据质量。使用FASTX(http://hannonlab.cshl.edu/fastx_toolkit/)移除低准确度的碱基和连接序列(adapter sequence)。然后,使用Tophat(Trapnell等人,2009年)和人类基因组(hg19)进行比对,并且使用重命名为RSeQC的EVER序列(Wang等人,2012年)来确定每个样品的数据量。此外,使用Cufflinks定量转录物的表达水平,并且比较以微尘分散液处理过的样本和正常样品的间的转录量(Trapnell等,2010年)。使用FDR调整后的p值<0.05的≥2.0倍变化的严格截止(cut-off),以确定当用直径为2.5μm的微尘分散液处理时显示出显著表达差异的基因。测量结果显示在下表2和图2中。
[表2]
实施例6:实时RT-PCR定量
将实施例3中所培养的正常人角质形成细胞用实施例2中提取的直径为2.5μm的微尘进行处理,该微尘的量为每1ml的细胞培养基有12.5μg。然后,使用下文表3中所示基因的引子(应用的生物系统引子)测量相对mRNA表达水平。将实施例1中所制备的提取物作为梅花提取物。
[表3]
用20ppm的梅花提取物处理培养基。在24小时之后,移除培养液,以2ml的磷酸盐缓冲盐水(PBS)洗涤细胞。然后,使用Trizol试剂(美国加州Carlsbad的Invitrogen公司)从细胞中分离RNA。用RNA套组(美国加州Valencia的QIAGEN的QIAGEN RNeasy kt)进一步纯化分离的RNA。然后,使用Agilent 2100 BioAnalyzer(美国加州Santa Clara的AgilentTechnologies公司)确定RNA的质量。使用反转录套组(美国加州Carlsbad的Invitrogen公司的Superscript Reverse Transcriptase(RT)套组)从RNA合成cDNA。使用表3中所示的引子通过实时反转录聚合酶链反应(Q-RT-PCR)定量分析cDNA。使用TaqMan基因表达测定套组(美国加州Foster City的Applied Biosystems公司)通过实时PCR评估细胞基因的改变。结果显示于图2。Q-RT-PCR和实时PCR都是根据Life Technologies分发的标准方案执行。具体的,执行40个下述循环:95℃达20秒,95℃达3秒,和60℃达30秒。
图2显示存在一基因,该基因的表达水平在由微尘刺激的皮肤细胞中增加或减少,并且图2显示以梅花提取物处理而减少介白素26γ(IL-36G)的表达水平。
因此,发现梅花提取物有效地保护皮肤细胞免受微尘的刺激,且抑制或防止上述特定基因的表达水平因刺激而改变,从而达到正常表达水平。
在下文中,将描述根据本发明的组合物的制剂实施例。然而,化妆品组合物、药物组合物、和保健功能食品组合物可以调配成各种其他形式。这些实施例仅用于说明目的,并非意在限制本发明的范畴。
制剂实施例1:片剂
根据已知制备片剂的方法,将100mg的根据本发明实施例的梅花提取物、400mg乳糖、400mg玉米淀粉、和2mg硬脂酸镁混合,且进行压片过程而制备片剂。
表4
成分 | 含量(mg) |
梅花提取物 | 100 |
乳糖 | 400 |
玉米淀粉 | 400 |
硬脂酸镁 | 2 |
制剂实施例2:胶囊
根据已知制备胶囊的方法,将100mg的根据本发明实施例的梅花提取物、400mg乳糖、400mg玉米淀粉、和2mg硬脂酸镁混合填充到明胶胶囊中,而制备胶囊。
表5
成分 | 含量(mg) |
梅花提取物 | 100 |
乳糖 | 400 |
玉米淀粉 | 400 |
硬脂酸镁 | 2 |
制剂实施例3:颗粒
使用流体化床造粒机,将50mg的根据本发明实施例的梅花提取物、250mg无水结晶葡萄糖、及550mg淀粉混合并且调配成颗粒。然后将颗粒装入小袋中。
表6
成分 | 含量(mg) |
梅花提取物 | 50 |
无水结晶葡萄糖 | 250 |
淀粉 | 550 |
制剂实施例4:肥皂
表7
制剂实施例5:润肤露
表8
成分 | 含量(%) |
梅花提取物 | 5.00 |
L-抗坏血酸-2-磷酸镁盐 | 1.00 |
水溶性胶原蛋白(1%水溶液) | 1.00 |
柠檬酸钠 | 0.10 |
柠檬酸 | 0.05 |
甘草提取物 | 0.20 |
1,3-丁二醇 | 3.00 |
纯水 | 余量 |
制剂实施例6:乳霜
表9
制剂实施例7:软膏
表10
成分 | 含量(%) |
梅花提取物 | 5.00 |
聚乙烯醇 | 13.00 |
L-抗坏血酸-2-磷酸镁盐 | 1.00 |
月桂酰基羟脯胺酸 | 1.00 |
水溶性胶原蛋白(1%水溶液) | 2.00 |
1,3-丁二醇 | 3.00 |
乙醇 | 5.00 |
纯水 | 余量 |
制剂实施例8:化妆液的制备
表11
成分 | 含量(%) |
梅花提取物 | 3.00 |
羟乙烯纤维素(2%水溶液) | 12.00 |
黄原胶(2%水溶液) | 2.00 |
1,3-丁二醇 | 6.00 |
浓缩甘油 | 4.00 |
透明质酸钠(1%水溶液) | 2.00 |
纯水 | 余量 |
制剂实施例9:保健食品
表12
成分 | 含量 |
梅花提取物 | 2mg |
维他命A醋酸盐 | 70μg |
维他命E | 1.0mg |
维他命B1 | 0.13mg |
维他命B2 | 0.15mg |
维他命B6 | 0.5mg |
维他命B12 | 0.2μg |
维他命C | 10mg |
生物素 | 10μg |
烟碱酰胺 | 1.7mg |
叶酸 | 50μg |
泛酸钙 | 0.5mg |
硫酸亚铁 | 1.75mg |
氧化锌 | 0.82mg |
碳酸镁 | 25.3mg |
磷酸二氢钾 | 15mg |
磷酸氢二钙 | 55mg |
柠檬酸钾 | 90mg |
碳酸钙 | 100mg |
氯化镁 | 24.8mg |
制剂实施例10:保健饮料
表13
成分 | 含量 |
梅花提取物 | 50mg |
柠檬酸 | 1000mg |
寡醣 | 100g |
牛磺酸 | 1g |
纯水 | 余量 |
Claims (10)
1.一种用于护理因微尘造成的皮肤细胞损伤的组合物,包括作为活性成分的梅花提取物(Prunus mume flower extract)。
2.如权利要求1所述的组合物,其特征在于,该梅花提取物是以至少一种提取溶剂所提取,该提取溶剂选自下述溶剂组成的群组:水、C1-C6无水或水合低级醇、丙酮、丁二醇、乙酸乙酯、乙酸二乙酯、二乙醚、苯、氯仿、及己烷。
3.如权利要求1所述的组合物,其特征在于,基于该组合物的总重量,该梅花提取物占0.000001重量%至30重量%。
4.如权利要求1所述的组合物,其特征在于,该组合物抑制IG-36G(NM_019619)的表达。
5.如权利要求4所述的组合物,其特征在于,该组合物对角质形成细胞作用。
6.如权利要求1所述的组合物,其特征在于,该微尘的粒径为2.5μm或更小。
7.如权利要求1所述的组合物,其特征在于,该梅花提取物是以10至500mg/kg/日的剂量给药。
8.如权利要求1所述的组合物,其特征在于,该组合物是化妆品组合物。
9.如权利要求1所述的组合物,其特征在于,该组合物是药物组合物。
10.如权利要求1所述的组合物,其特征在于,该组合物是保健功能食品组合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0121801 | 2017-09-21 | ||
KR1020170121801A KR102087188B1 (ko) | 2017-09-21 | 2017-09-21 | 매화꽃 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물 |
PCT/KR2018/009253 WO2019059527A1 (ko) | 2017-09-21 | 2018-08-13 | 매화꽃 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111712226A true CN111712226A (zh) | 2020-09-25 |
CN111712226B CN111712226B (zh) | 2023-03-31 |
Family
ID=65811403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880075567.1A Active CN111712226B (zh) | 2017-09-21 | 2018-08-13 | 用于护理因微尘所造成的皮肤细胞损伤的含有梅花提取物的组合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20200246413A1 (zh) |
JP (1) | JP7198275B2 (zh) |
KR (1) | KR102087188B1 (zh) |
CN (1) | CN111712226B (zh) |
SG (1) | SG11202002451TA (zh) |
TW (1) | TWI775944B (zh) |
WO (1) | WO2019059527A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220011402A (ko) | 2020-07-21 | 2022-01-28 | (주)아모레퍼시픽 | 피부 각질의 분화 이상 정상화용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002370922A (ja) * | 2001-06-15 | 2002-12-24 | Azuma Noen:Kk | 梅抽出物を含む化粧品 |
JP2004115542A (ja) * | 1998-12-25 | 2004-04-15 | Azuma Noen:Kk | 薬効を有する梅抽出物およびそれを含有する組成物 |
KR20110051880A (ko) * | 2009-11-11 | 2011-05-18 | (주)아모레퍼시픽 | 피부 보습 및 탄력 개선 화장료 조성물 |
WO2012033368A2 (ko) * | 2010-09-08 | 2012-03-15 | (주)아모레퍼시픽 | 오매 추출물을 함유하는 피부 외용제 조성물 |
KR20160119703A (ko) * | 2015-04-06 | 2016-10-14 | (주)아모레퍼시픽 | 미세먼지에 의한 피부 손상 진단용 조성물 및 갈랑긴을 유효성분으로 포함하는 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005097219A (ja) | 2003-09-26 | 2005-04-14 | Noriyasu Hori | 梅花香油 |
CN101305796A (zh) * | 2008-07-04 | 2008-11-19 | 昆明七彩云花生物科技有限公司 | 用食用植物花卉或花卉提取物制备的胶囊与口服液 |
KR20130035408A (ko) * | 2011-09-30 | 2013-04-09 | (주)아모레퍼시픽 | 오매 추출물을 포함하는 피부 자극 완화용 조성물 |
-
2017
- 2017-09-21 KR KR1020170121801A patent/KR102087188B1/ko active IP Right Grant
-
2018
- 2018-08-13 SG SG11202002451TA patent/SG11202002451TA/en unknown
- 2018-08-13 CN CN201880075567.1A patent/CN111712226B/zh active Active
- 2018-08-13 US US16/648,946 patent/US20200246413A1/en not_active Abandoned
- 2018-08-13 WO PCT/KR2018/009253 patent/WO2019059527A1/ko active Application Filing
- 2018-08-13 JP JP2020516596A patent/JP7198275B2/ja active Active
- 2018-09-18 TW TW107132776A patent/TWI775944B/zh active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004115542A (ja) * | 1998-12-25 | 2004-04-15 | Azuma Noen:Kk | 薬効を有する梅抽出物およびそれを含有する組成物 |
JP2002370922A (ja) * | 2001-06-15 | 2002-12-24 | Azuma Noen:Kk | 梅抽出物を含む化粧品 |
KR20110051880A (ko) * | 2009-11-11 | 2011-05-18 | (주)아모레퍼시픽 | 피부 보습 및 탄력 개선 화장료 조성물 |
WO2012033368A2 (ko) * | 2010-09-08 | 2012-03-15 | (주)아모레퍼시픽 | 오매 추출물을 함유하는 피부 외용제 조성물 |
KR20160119703A (ko) * | 2015-04-06 | 2016-10-14 | (주)아모레퍼시픽 | 미세먼지에 의한 피부 손상 진단용 조성물 및 갈랑긴을 유효성분으로 포함하는 조성물 |
Non-Patent Citations (1)
Title |
---|
AHN, YONG CHAN: "2合1梅花保湿去角质,清空死皮细胞,只留下水分", 《BEAUTY NURY - COSMETICS NEWSPAPER》 * |
Also Published As
Publication number | Publication date |
---|---|
JP7198275B2 (ja) | 2022-12-28 |
KR102087188B1 (ko) | 2020-03-11 |
TWI775944B (zh) | 2022-09-01 |
CN111712226B (zh) | 2023-03-31 |
US20200246413A1 (en) | 2020-08-06 |
SG11202002451TA (en) | 2020-04-29 |
TW201922120A (zh) | 2019-06-16 |
JP2020534318A (ja) | 2020-11-26 |
KR20190033256A (ko) | 2019-03-29 |
WO2019059527A1 (ko) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111712226B (zh) | 用于护理因微尘所造成的皮肤细胞损伤的含有梅花提取物的组合物 | |
KR20190038106A (ko) | 발효차 추출물을 포함하는 피부장벽 강화용 조성물 | |
KR102090133B1 (ko) | 무궁화 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물 | |
KR102164346B1 (ko) | 발효차 추출물을 포함하는 항산화, 항노화 또는 항염 조성물 | |
KR102212626B1 (ko) | 박하초 추출물을 포함하는 피부장벽 강화용 조성물 | |
KR102429852B1 (ko) | 차나무 뿌리 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물 | |
US11433110B2 (en) | Composition for treating fine dust-caused skin cell damage or for inhibiting antimicrobial peptide, comprising Hibiscus syriacus extract | |
KR102212627B1 (ko) | 박하초 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물 | |
AU2018341302B2 (en) | Antioxidizing, antiaging, or anti-inflammatory composition for strengthening skin barrier and caring for skin cell damage caused by fine dust including fermented tea extract | |
JP7158426B2 (ja) | メンタアルベンシス抽出物を含む微塵による皮膚細胞損傷ケア用、皮膚バリア強化用、及び抗老化又は抗炎症組成物 | |
US11666620B2 (en) | Method for treatment of fine dust-caused skin cell damage, reinforcement of skin barrier, anti-aging, and anti-inflammation | |
KR102152753B1 (ko) | 발효차 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물 | |
KR102212625B1 (ko) | 박하초 추출물을 포함하는 항노화 또는 항염 조성물 | |
KR102429851B1 (ko) | 차나무 뿌리 추출물을 포함하는 항노화 또는 항염 조성물 | |
KR102429850B1 (ko) | 차나무 뿌리 추출물을 포함하는 피부장벽 강화용 조성물 | |
KR20190037879A (ko) | 무궁화 추출물을 포함하는 항균성 펩티드 저해용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40031491 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |